Opinion
Video
FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC
Panelists discuss how recently FDA-approved therapies, including nadofaragene firadenovec, gemcitabine, and docetaxel, offer alternative treatment options for BCG-unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC), each with distinct mechanisms and administration methods.
Physician Summary:
Three recently FDA-approved agents for the treatment of high-risk, BCG-unresponsive NMIBC provide alternative options for patients who do not respond to standard BCG therapy. Here is a brief overview of each therapy, their mechanisms of action, and methods of administration:
- Nadofaragene firadenovec (Adstiladrin)
- Mechanism of Action: Nadofaragene firadenovec is a gene therapy that delivers a modified adenovirus encoding the gene for interferon-alfa 2b directly into the bladder. This induces a local immune response that targets cancer cells, particularly for carcinoma in situ and papillary tumors.
- Administration: Administered via intravesical instillation, typically once every 3 months. The viral vector is delivered into the bladder through a catheter, and the therapy works by utilizing the patient’s own immune system to recognize and destroy tumor cells.
- Other Recently Approved Agents (eg, gemcitabine and docetaxel)
- Mechanism of Action: These are chemotherapy agents. Gemcitabine works by inhibiting DNA synthesis in rapidly dividing cancer cells, while docetaxel disrupts microtubule function to prevent cancer cell division.
- Administration: Both are administered via intravesical instillation, though schedules and frequency may vary. Gemcitabine is usually given once a week, while docetaxel is often given in a similar regimen, depending on the patient’s specific clinical needs.
These novel therapies provide crucial options for patients with BCG-unresponsive NMIBC, each utilizing different mechanisms—immune modulation via gene therapy (nadofaragene firadenovec) and direct cytotoxic effects (gemcitabine and docetaxel).
